HighTower Advisors
TCRT icon

HighTower Advisors’s Alaunos Therapeutics TCRT Stock Holding History

HighTower Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67
Closed -$4K – 3394
2022
Q2 		$4K Buy
+67
New +$6.4K ﹤0.01% 3141
2018
Q3 		– Sell
-13
Closed -$1K – 2415
2018
Q2 		$1K Buy
+13
New +$8.24K ﹤0.01% 2226
2014
Q2 		– Sell
-159
Closed -$1K – 1709
2014
Q1 		$1K Hold
159
– – ﹤0.01% 1584
2013
Q4 		$10K Buy
+159
New +$94.7K ﹤0.01% 1512
2013
Q3 		– Sell
-200
Closed -$8K – 1452
2013
Q2 		$8K Buy
+200
New +$55.5K ﹤0.01% 1280

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCA
Magnolia Capital Advisors Jackson, Mississippi $509M AUM 18.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

HighTower Advisors's TCRT Position: Q4 2023 in Review

HighTower Advisors sold out of Alaunos Therapeutics (TCRT) in Q4 2023, closing a stake of 367 shares — an estimated $7K sold.

HighTower Advisors first reported a position in TCRT in Q2 2013 and held it in 41 quarters. The position peaked at $827K in Q2 2019. 82 funds tracked by Wall St. Rank hold TCRT as of Q4 2023.

  • HighTower Advisors reported no remaining Alaunos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • HighTower Advisors sold 367 Alaunos Therapeutics shares in Q4 2023, an estimated $7K.
  • HighTower Advisors first reported a position in Alaunos Therapeutics in Q2 2013 and held it in 41 quarters.
  • HighTower Advisors's Alaunos Therapeutics position peaked at $827K in Q2 2019.
  • 82 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2023.

Based on HighTower Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.